Profile
GELS ZTS TAK HLN TEVA VTRS
Company Name Gelteq Limited Ordinary Shares Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $14.25M $79.21B $43.18B $42.82B $19.05B $15.58B
Employees 0.01K 14.10K 49.28K 25.41K 37.00K 32.00K
CEO Mr. Nathan Jacob Givoni Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Mr. Brian S. Roman
Ratings
GELS ZTS TAK HLN TEVA VTRS
Quant Rating Score 3 3 3 1 3
Quant Rating Neutral Neutral Neutral Strong Sell Neutral
Trading
GELS ZTS TAK HLN TEVA VTRS
Last Close $1.61 $175.56 $13.62 $9.48 $16.81 $13.05
High 52 $2.85 $199.94 $15.08 $10.69 $18.96 $13.53
Low 52 $1.53 $145.54 $12.6 $8.01 $10.44 $10.05
Price vs. 52 Week High -43.51 % -12.19 % -9.68 % -11.32 % -11.34 % -3.55 %
Price vs. 52 Week Low 5.23 % 20.63 % 8.1 % 18.35 % 61.02 % 29.85 %
Total Return
GELS ZTS TAK HLN TEVA VTRS
1 Month Return 0 % -9.17 % -4.95 % -6.05 % -6.35 % 10.97 %
3 Month Return 0 % -4.38 % -7.72 % -3.76 % -7.99 % 11.92 %
6 Month Return 0 % 0.67 % 2.56 % 11.4 % 0 % 17.89 %
9 Month Return 0 % -5.89 % -8.1 % 14.49 % 28.62 % -1.44 %
YTD Return 0 % -11.05 % -4.56 % 15.19 % 61.02 % 20.5 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
GELS ZTS TAK HLN TEVA VTRS
Dividend Yield Percentage (TTM) - 1.23 % 4.65 % 2.11 % - 3.68 %
Dividend Paid and Capex Coverage Ration (TTM) - 2.1 % 1.29 % - 5.06 % 2.39 %
Dividend Per Share (TTM) - 2.16 % 0.63 % 0.16 % - 0.48 %
Payout Ratio (TTM) - 31.44 % 101.62 % - - -65.15 %
Profitability
GELS ZTS TAK HLN TEVA VTRS
Gross Profit Margin TTM 68.87 % 62.47 % 59.91 % 49.87 % 40.26 %
Return on Assets TTM 16.93 % 1.99 % 3.26 % -2.38 % -1.97 %
Return on Equity TTM 47.99 % 4.04 % 6.54 % -14.58 % -4.43 %
Return on Capital Employed TTM 26.64 % 5.27 % 7.25 % 7.66 % -0.71 %
Net Income Per EBT TTM 79.65 % 109.03 % 65.38 % 175.89 % 92.81 %
EBT Per Ebit TTM 90.51 % 41.38 % 82.66 % -26.34 % 359.67 %
EBIT Per Revenue TTM 36.83 % 14.14 % 17.88 % 12.76 % -1.76 %
Cash Flow To Debt Ratio TTM 44.8 % 17.01 % - 13 % 13.05 %
Receivables Turnover TTM 6.49 6.3 5.27 4.85 4.04
Payables Turnover TTM 7.05 4.13 1.25 3.55 7.23
Inventory Turnover TTM 1.18 1.41 3.09 2.13 2.2
Fixed Asset Turnover TTM 259.93 % 240.84 % 604.62 % 278.05 % 561.67 %
Asset Turnover TTM 63.75 % 31.2 % 33.71 % 40.19 % 33.6 %
Operating Cash Flow Per Share TTM 6.5 545.34 - 2.18 1.93
Free Cash Flow Per Share TTM 5.1 309.43 - 1.75 1.6
Cash Per Share TTM 378.45 % 57513.46 % 5.72 % 292.94 % 157.41 %
Operating Cash Flow Sales Ratio TTM 32.18 % 18.9 % - 14.71 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 78.37 % 56.74 % - 80.23 % 83.19 %
Cash Flow Coverage Ratios TTM 44.8 % 17.01 % - 13 % 13.05 %
Price To Free Cash Flows Ratio TTM 34.32 13.8 - 9.62 8.14
Price To Operating Cash Flows Ratio TTM 27 3.89 - 7.72 6.77
Price Cash Flow Ratio TTM 27 3.89 - 7.72 6.77
Income Statement (TTM)
GELS ZTS TAK HLN TEVA VTRS
Revenue $8.54B $4263.76B $11.3B $15.85B $15.43B
Gross Profit $5.83B $2321.31B $6.96B $7.65B $6.44B
Gross Profit Ratio 68.28% 54.44% 61.6% 48.25% 41.74%
EBITDA $3.69B $900.33B $2.35B $4.33B $3.52B
Net Income $2.34B $144.07B $1.05B $-0.56B $0.05B
EPS Diluted 5.07 91.16 0.11 -0.5 0.05
Balance Sheet (MRQ)
GELS ZTS TAK HLN TEVA VTRS
Long Term Debt $6.75B $5029.93B $8.95B $18.48B $16.35B
Total Liabilities $9.3B $7834.79B $17.33B $35.35B $27.22B
Total Equity $4.99B $7274.01B $16.73B $8.13B $20.47B
Total Investments $0.02B $683.22B $0.07B $0.01B $1.33B
Total Debt $6.76B $5463.39B $9.46B $20.15B $18.37B
Total Assets $14.29B $15108.79B $34.06B $43.48B $47.69B
Cash Flow Statement (TTM)
GELS ZTS TAK HLN TEVA VTRS
Net Income $2.34B $144.07B $1.05B $-0.62B $0.05B
Inventory $-0.36B $-115.74B $-0.13B $0B $-0.61B
Dividends Paid $-0.69B $-287.19B $-0.39B $0B $-0.58B
Operating Cash Flow $2.35B $640.32B $1.72B $1.37B $2.8B
Capital Expenditure $-0.73B $-480.73B $-0.34B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.24
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.37
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 12.42
ALVOW Alvotech 3.4
AMPH Amphastar Pharmaceuticals, Inc. 44.09
AMRX Amneal Pharmaceuticals, Inc. 8.41
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 55.1
AQST Aquestive Therapeutics, Inc. 4.735
ASRT Assertio Holdings, Inc. 0.95
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 10.75
AYTU Aytu BioPharma, Inc. 1.49
Unlock